Astrana Health FY2025 revenue $3.18B (+56% YoY), adjusted EBITDA $205.4M; material weakness delays 10-K filing

Astrana Health, Inc.

FY2025 total revenue $3.18B (+56% YoY); at high end of guidance; Care Partners revenue $3.02B (+55%).
Adjusted EBITDA $205.4M (+21% YoY); adjusted diluted EPS $2.20; net income $22.5M, GAAP EPS $0.46.
Q4 revenue $950.5M (+43% YoY); adjusted EBITDA $52.5M (+50%); adjusted EPS $0.54.
Board doubled share repurchase authorization to $100M; $35.9M remained at Dec 31, 2025.
Anticipates material weakness in internal controls over acquisition/purchase accounting; expects to file 10-K within 15-day extension.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.